[Congressional Record Volume 167, Number 88 (Thursday, May 20, 2021)]
[Senate]
[Pages S3312-S3313]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 1917. Mr. RUBIO (for himself and Mr. Coons) submitted an amendment 
intended to be proposed to amendment SA 1502 proposed by Mr. Schumer to 
the bill S. 1260, to establish a new Directorate for Technology and 
Innovation in the National Science Foundation, to establish a regional 
technology hub program, to require a strategy and report on economic 
security, science, research, innovation, manufacturing, and job 
creation, to establish a critical supply chain resiliency program, and 
for other purposes; which was ordered to lie on the table; as follows:
       At the end of section 2402 of division B, add the 
     following:

[[Page S3313]]

       (k) Reviews and Recommendations Regarding Technology at the 
     Centers for Innovation in Advanced Development and 
     Manufacturing and the Medical Countermeasures Advanced 
     Development and Manufacturing Facility.--
       (1) In general.--The Secretary of Commerce, acting through 
     the Under Secretary of Commerce for Standards and Technology, 
     shall seek to enter into an agreement with the National 
     Institute for Innovation in Manufacturing Biopharmaceuticals 
     (NIIMBL) to perform the services covered by this subsection.
       (2) Review and recommendations.--Under an agreement between 
     the Secretary and the National Institute for Innovation in 
     Manufacturing Biopharmaceuticals, the National Institute for 
     Innovation in Manufacturing Biopharmaceuticals shall, in 
     collaboration with the Director of the Biomedical Advanced 
     Research and Development Authority (BARDA) of the Department 
     of Health and Human Services and the Secretary of Defense--
       (A) review technology at the Centers for Innovation in 
     Advanced Development and Manufacturing of the Department of 
     Health and Human Services and the Medical Countermeasures 
     Advanced Development and Manufacturing facility of the 
     Department of Defense;
       (B) develop recommendations for means to implement 
     innovative approaches to advance United States domestic 
     biopharmaceutical manufacturing capabilities and to ensure 
     that the Centers for Innovation in Advanced Development and 
     Manufacturing and the Medical Countermeasures Advanced 
     Development and Manufacturing facility have state-of-the-art 
     capabilities aligned with those available to the private 
     sector; and
       (C) identify other opportunities and priorities to improve 
     the United States public health and medical preparedness and 
     response capabilities and domestic biopharmaceutical 
     manufacturing capabilities.
                                 ______